Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)

Ítems similars

• Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
  per: van der Heijde, D, et al.
  Publicat: (2006)
• CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
  per: Wordsworth, P, et al.
  Publicat: (2009)
• Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas
  per: Wordsworth, P, et al.
  Publicat: (2008)
• Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.
  per: Van der Heijde, D, et al.
  Publicat: (2005)
• Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
  per: Revicki, D, et al.
  Publicat: (2008)